Table 1.
Therapeutic approaches for various cancers through pDCs.
| Type of cancers | Role of pDCs | Therapeutic approach | References |
|---|---|---|---|
| Melanoma | Limit IFN-α secretion, recruit Tregs and enhance immunosuppression. | TLR9-agonist | (45, 48, 49) |
| TLR7-agonist | (46, 50) | ||
| TLR-4 ligand | (51) | ||
| Pim-3-targeting bifunctional shRNA | (52) | ||
| IFN-α therapy | (53) | ||
| IFN-α therapy + checkpoint inhibitor | (54) | ||
| pDC-based vaccination | (55–57) | ||
| Lung cancer | Induce immunosuppression and promote the proliferation of lung cancer cells. | TLR4-agonist | (58) |
| Gastric cancer | Promote the differentiation of naive CD4+ T cells into Tregs and facilitate tumor immune escape. | TLR3 agonist | (59) |
| Breast cancer | Contribute to the immune escape of breast cancer cells and promote tumor growth. | – | – |
| Liver cancer | Promote Tregs to produce IL-10, thereby inhibit T cell responses and assist immunosuppression and tumor progression. | – | – |
| Squamous cell carcinoma | Limit IFN-α secretion and promote tumor progression. | CD317 antibody | (60) |
| Leukemia | Recruit Tregs into CMML. | CD123-targeted therapy | (61) |
| Ovarian cancer | Limit IFN-α secretion recruit Tregs and enhance immunosuppression | Prophylactic vaccines | (62) |